NCT02227823View on ClinicalTrials.gov

Safety and Efficacy Study of Pyridostigmine on Patients With Spinal Muscular Atrophy Type 3

PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions
Spinal Muscular Atrophy Type 3
Interventions
DRUG

Pyridostigmine Bromide

Trial Locations (1)

4000

Centre de référence des maladies neuromusculaire, Centre Hospitalier Régional de la Citadelle, Liège

All Listed Sponsors
lead

Centre Hospitalier Régional de la Citadelle

OTHER

NCT02227823 - Safety and Efficacy Study of Pyridostigmine on Patients With Spinal Muscular Atrophy Type 3 | Biotech Hunter | Biotech Hunter